A COMPARATIVE ASSESSMENT OF TWO ANTIDIABETIC MEDICATION ON GLUCOSE LEVEL LIPID PROFILE AND CBC IN A RAT MODEL WITH TYPE II DIABETES MELLITUS
Downloads
Objective: Glycemic control is still the most important aspect of T2DM treatment sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, and metformin therapy is effective and well tolerated in patients with T2DM and is the first of the several recommended treatment options. Since empagliflozin is poorly studied solely or in comparison with metformin, the current study aims to compare the influence of these drugs on glycemic levels individually in patients with type 2 diabetes mellitus (T2DM). this study aimed to evaluate both medication effects on the Lipid profile, glycemic level and CBC in comparison with control groups of the animals experimental. Method: The study was a quantitative experimental investigation (cross-sectional study) that contrasted the influence of metformin and empagliflozin on the short-term glycemic level. This study included an animal Experiment, forty healthy, Swiss male albino rats of approximately (10–12 weeks old) with weights of (150–200 g) were used in this research. The Induction of type 2 Diabetes Mellitus was performed through hyperlipidemia and insulin resistant model which was developed using the high fat and high sugar diet. Blood samples were analysed for basic and advanced investigations. electrochemiluminescence (E.C.L.) technology was used for immunoassay analysis to measure Lipid profile, Fasting blood glucose level, and Hemoglobin A1C (HbA1c) Test. Results: The results of the animal’s experiment showed that the RBC number decreased significantly in rats-DM II group C treated with empagliflozin compared to the group A & B, the RBC decreased by 18% in group C, and 8% in Group B respectively. The blood sugar level decreased significantly in rats-DM II group B treated with metformin and in group C treated with empagliflozin compared to group A who was untreated, sugar levels decreased by 43% in Group B, and 35 % in group C respectively. results also showed a significant decrease in triglyceride concentration was observed in both treated diabetic rats groups (B&C) compared; the triglyceride level in the nontreated group (A) was, however, reduced by 44% in the diabetic treated with 500 mg/kg metformin and 40% in the diabetic treated with 10 mg/kg empagliflozin. Novelty: Metformin and empagliflozin have been shown through clinical studies an improve in the lowering of blood glucose. Both medications significantly improved glycemic control and lipid profile.
R. Khursheed et al., “Treatment strategies against diabetes: Success so far and challenges ahead,” Eur. J. Pharmacol., vol. 862, p. 172625, 2019.
A. Qaseem et al., “Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus,” Ann. Intern. Med., vol. 168, no. 8, pp. 569–576, 2018.
A. J. Al-Mosawi, “The use of metformin in non-diabetic obesity: An educational article and expert opinion,” J. Cancer Res. Cell. Ther., vol. 7, no. 3, 2023.
X. Yang, Z. Xu, C. Zhang, Z. Cai, and J. Zhang, “Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells,” Biochim. Biophys. Acta Mol. Basis Dis., vol. 1863, no. 8, pp. 1984–1990, 2017.
D. J. Sansome et al., “Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids,” Diabetes Obes. Metab., vol. 22, no. 2, pp. 141–148, 2020.
T. E. LaMoia and G. I. Shulman, “Cellular and molecular mechanisms of metformin action,” Endocr. Rev., vol. 42, no. 1, pp. 77–96, 2021.
E. Brown, S. P. Rajeev, D. J. Cuthbertson, and J. P. Wilding, “A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors,” Diabetes Obes. Metab., vol. 21, pp. 9–18, 2019.
G. Chawla and K. K. Chaudhary, “A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus,” Diabetes Metab. Syndr., vol. 13, no. 3, pp. 2001–2008, 2019.
C. S. Wilcox, “Antihypertensive and renal mechanisms of SGLT2 inhibitors,” Hypertension, vol. 75, no. 4, pp. 894–901, 2020.
L. Demirtas et al., “Association of hematological indices with diabetes, impaired glucose regulation and microvascular complications of diabetes,” Int. J. Clin. Exp. Med., vol. 8, no. 7, pp. 11420–11427, 2015.
Z.-S. Wang et al., “Red blood cell count as an indicator of microvascular complications in Chinese patients with type 2 diabetes mellitus,” Vasc. Health Risk Manag., vol. 9, pp. 237–243, 2013.
G. R. Gabreanu and S. Angelescu, “Erythrocyte membrane in type 2 diabetes mellitus,” Discoveries, vol. 4, no. 2, p. e60, 2016.
Y. I. Cho, M. P. Mooney, and D. J. Cho, “Hemorheological disorders in diabetes mellitus,” J. Diabetes Sci. Technol., vol. 2, no. 6, pp. 1130–1138, 2008.
A. G. Shenoy and R. K. Goyal, “Improvement of insulin sensitivity by perindopril in spontaneously hypertensive and streptozotocin-diabetic rats,” Indian J. Pharmacol., vol. 34, pp. 156–164, 2002.
G. Formoso et al., “Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects,” Diabetes Metab. Res. Rev., vol. 24, pp. 231–237, 2008.
I. Dolasık et al., “The effect of metformin on mean platelet volume in diabetic patients,” Platelets, vol. 24, pp. 118–121, 2013.
S. T. W. Cheng et al., “The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes,” PLoS ONE, vol. 11, no. 1, p. e0147391, 2016.
V. Vallon, “The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus,” Annu. Rev. Med., vol. 66, pp. 255–270, 2015.
L. Chen, T. Klein, and P. S. Leung, “Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice,” Curr. Mol. Med., vol. 12, no. 8, pp. 995–1004, 2012.
R. P. Robertson, “Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes,” J. Biol. Chem., vol. 279, no. 41, pp. 42351–42354, 2004.
L. K. Olson et al., “Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription,” J. Clin. Invest., vol. 92, no. 1, pp. 514–519, 1993.
E. J. de Koning, S. Bonner-Weir, and T. J. Rabelink, “Preservation of beta-cell function by targeting beta-cell mass,” Trends Pharmacol. Sci., vol. 29, no. 4, pp. 218–227, 2008.
LiverTox, “Metformin,” Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
Z. Y. Chen, “A case of acute drug-induced liver injury caused by oral metformin sustained-release tablets,” Chin. J. Gen. Pract., vol. 19, no. 4, pp. 366–367, 2020.
A. Blum et al., “Metformin-induced hemolytic anemia,” Isr. Med. Assoc. J., vol. 13, pp. 444–445, 2011.
G. Garratty, “Drug-induced immune hemolytic anemia,” Hematology, pp. 73–79, 2009.
M. L. Contreras-Zentella and R. Hernández-Muñoz, “Is liver enzyme release really associated with cell necrosis induced by oxidant stress?” Oxid. Med. Cell. Longev., vol. 2016, p. 3529149, 2016.
S. Lasker et al., “High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation,” Sci. Rep., vol. 9, p. 20026, 2019.
M. S. Kuchay et al., “Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (E-LIFT Trial),” Diabetes Care, vol. 41, no. 8, pp. 1801–1808, 2018.
Y. Aso et al., “Impact of dapagliflozin on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease,” Int. J. Clin. Pract., vol. 73, no. 5, p. e13335, 2019.
B. Zinman et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” N. Engl. J. Med., vol. 373, no. 22, pp. 2117–2128, 2015.
C. L. Triplitt, T. Repas, and C. Alvarez, “Diabetes mellitus,” in Pharmacotherapy: A Pathophysiologic Approach, 10th ed., J. T. DiPiro et al., Eds. New York, NY, USA: McGraw-Hill, 2017.
J. Zhou, S. Massey, D. Story, and L. Li, “Metformin: An old drug with new applications,” Int. J. Mol. Sci., vol. 19, p. 2863, 2018.
L. Merker et al., “Empagliflozin as add-on to metformin in people with type 2 diabetes,” Diabet. Med., vol. 32, no. 12, pp. 1555–1567, 2015.
F. Zaccardi et al., “Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis,” Diabetes Obes. Metab., vol. 18, no. 8, pp. 783–794, 2016.
S. Kohler et al., “Safety and tolerability of empagliflozin in patients with type 2 diabetes,” Clin. Ther., vol. 38, pp. 1299–1313, 2016.
F. Briand et al., “Empagliflozin moderately increases LDL cholesterol levels through reduced LDL catabolism,” Diabetes, vol. 65, pp. 2032–2038, 2016.
J. Rosenstock et al., “Efficacy and safety of empagliflozin as add-on to metformin in type 2 diabetes with mild hyperglycaemia,” Diabetes Obes. Metab., vol. 15, pp. 1154–1160, 2013.
T. Jojima et al., “Empagliflozin increases plasma levels of campesterol in patients with type 2 diabetes,” Int. J. Cardiol., vol. 331, pp. 243–248, 2021.
B. Zinman et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” N. Engl. J. Med., vol. 373, no. 22, pp. 2117–2128, 2015.
D. Basu et al., “Mechanism of increased LDL and decreased triglycerides with SGLT2 inhibition,” Arterioscler. Thromb. Vasc. Biol., vol. 38, no. 9, pp. 2207–2216, 2018.
T. Jojima et al., “Empagliflozin prevents steatohepatitis in a mouse model of non-alcoholic steatohepatitis and diabetes,” Diabetol. Metab. Syndr., vol. 8, p. 45, 2016.
V. S. Nunes et al., “HDL-C concentration is related to markers of cholesterol absorption and synthesis,” Clin. Chim. Acta, vol. 381, pp. 168–173, 2007.
R. E. Ostlund Jr. et al., “Gastrointestinal absorption and plasma kinetics of soy phytosterols and phytostanols in humans,” Am. J. Physiol. Endocrinol. Metab., vol. 282, no. 4, pp. E911–E916, 2002.
S. S. Lund et al., “Potential relevance of changes in haematocrit to lipid parameters with empagliflozin,” Diabetologia, vol. 58, p. S360, 2015.
R. DeFronzo, G. A. Fleming, K. Chen, and T. A. Bicsak, “Metformin-associated lactic acidosis: Current perspectives on causes and risk,” Metabolism, vol. 65, no. 2, pp. 20–29, 2016.
R. Chilton et al., “Effects of empagliflozin on blood pressure and markers of arterial stiffness,” Diabetes Obes. Metab., vol. 17, pp. 1180–1193, 2015.
V. Vallon et al., “SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in diabetic mice,” Am. J. Physiol. Renal Physiol., vol. 306, pp. F194–F204, 2014.
M. Skrtić et al., “Glomerular haemodynamic responses to SGLT2 inhibition in type 1 diabetes,” Diabetologia, vol. 57, pp. 2599–2602, 2014.
B. Zinman et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” N. Engl. J. Med., vol. 373, pp. 2117–2128, 2015.
D. Z. Cherney et al., “Sodium glucose cotransporter-2 inhibition and intrarenal RAS activity in type 1 diabetes,” Kidney Int., vol. 86, pp. 1057–1058, 2014.
K. D. Burns and D. Cherney, “Renal angiotensinogen and SGLT2 inhibition,” Am. J. Nephrol., vol. 49, no. 4, pp. 328–330, 2019.
P. Perrone-Filardi et al., “Mechanisms linking empagliflozin to cardiovascular and renal protection,” Int. J. Cardiol., vol. 241, pp. 450–456, 2017.
T. C. Woods et al., “Canagliflozin prevents kidney injury and hypertension in type 2 diabetes,” Am. J. Nephrol., vol. 49, no. 4, pp. 331–342, 2019.
N. C. Gamit et al., “Effects of metformin on C-reactive protein level in type 2 diabetes mellitus,” Int. J. Basic Clin. Pharmacol., vol. 4, no. 1, pp. 46–50, 2017.
W. T. Garvey et al., “Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes,” Metabolism, vol. 85, pp. 32–37, 2018.
S. A. Tan and L. Tan, “Empagliflozin and canagliflozin attenuate inflammatory cytokines,” J. Am. Coll. Cardiol., vol. 71, p. A1830, 2018.
J. H. Han et al., “The beneficial effects of empagliflozin on atherosclerosis in ApoE−/− mice,” Diabetologia, vol. 60, pp. 364–376, 2017.
R. Suvarna et al., “Effect of metformin treatment on inflammatory markers in type 2 diabetes mellitus: A systematic review and meta-analysis,” J. Appl. Pharm. Sci., vol. 12, no. 4, pp. 001–011, 2022.
Copyright (c) 2026 Barakat Wathiq Al-Awdi
This work is licensed under a Creative Commons Attribution 4.0 International License.
